Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker PALI
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 9, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Guy Levy | 15.00M | 8.6% | SCHEDULE 13G/A ↗ |
| Nov 9, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Soleus GP, LLC | 15.00M | 8.6% | SCHEDULE 13G/A ↗ |
| Nov 9, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Soleus Capital Management, L.P. | 15.00M | 8.6% | SCHEDULE 13G/A ↗ |
| Nov 9, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Soleus Capital Group, LLC | 15.00M | 8.6% | SCHEDULE 13G/A ↗ |
| Nov 9, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Soleus Capital, LLC | 15.00M | 8.6% | SCHEDULE 13G/A ↗ |
| Nov 9, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Soleus Capital Master Fund, L.P. | 15.00M | 8.6% | SCHEDULE 13G/A ↗ |
| Oct 30, 2026 | SCHEDULE 13G | PALI Palisade Bio, Inc. | Vanguard Capital Management | 9.00M | 5.2% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Michael Kramarz | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Robert Egen Atkinson | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Commodore Capital Master LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Commodore Capital LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Guy Levy | 13.06M | 7.5% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Soleus GP, LLC | 13.06M | 7.5% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Soleus Capital Management, L.P. | 13.06M | 7.5% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Soleus Capital Group, LLC | 13.06M | 7.5% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Soleus Capital, LLC | 13.06M | 7.5% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Soleus Capital Master Fund, L.P. | 13.06M | 7.5% | SCHEDULE 13G/A ↗ |
| Jul 29, 2026 | SCHEDULE 13G | PALI Palisade Bio, Inc. | BlackRock, Inc. | 10.44M | 6.0% | SCHEDULE 13G ↗ |
| May 27, 2026 | SCHEDULE 13G | PALI Palisade Bio, Inc. | Guy Levy | 9.35M | 5.4% | SCHEDULE 13G ↗ |
| May 27, 2026 | SCHEDULE 13G | PALI Palisade Bio, Inc. | Soleus GP, LLC | 9.35M | 5.4% | SCHEDULE 13G ↗ |
| May 27, 2026 | SCHEDULE 13G | PALI Palisade Bio, Inc. | Soleus Capital Management, L.P. | 9.35M | 5.4% | SCHEDULE 13G ↗ |
| May 27, 2026 | SCHEDULE 13G | PALI Palisade Bio, Inc. | Soleus Capital Group, LLC | 9.35M | 5.4% | SCHEDULE 13G ↗ |
| May 27, 2026 | SCHEDULE 13G | PALI Palisade Bio, Inc. | Soleus Capital, LLC | 9.35M | 5.4% | SCHEDULE 13G ↗ |
| May 27, 2026 | SCHEDULE 13G | PALI Palisade Bio, Inc. | Soleus Capital Master Fund, L.P. | 9.35M | 5.4% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Michael Kramarz | 12.37M | 7.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Robert Egen Atkinson | 12.37M | 7.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Commodore Capital Master LP | 12.37M | 7.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Commodore Capital LP | 12.37M | 7.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | RA Capital Healthcare Fund, L.P. | 17.62M | 9.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Rajeev Shah | 17.62M | 9.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Peter Kolchinsky | 17.62M | 9.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | RA Capital Management, L.P. | 17.62M | 9.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Perceptive Life Sciences Master Fund, Ltd. | 14.11M | 7.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Joseph Edelman | 14.11M | 7.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Perceptive Advisors LLC | 14.11M | 7.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G | PALI Palisade Bio, Inc. | Columbia Management Investment Advisers, LLC | 8.71M | 5.3% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | PALI Palisade Bio, Inc. | Ameriprise Financial, Inc. | 8.71M | 5.3% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Steven A. Cohen | 411,772 | 0.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Point72 Capital Advisors, Inc. | 411,772 | 0.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Point72 Asset Management, L.P. | 411,772 | 0.2% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | William Blank | 4.50M | 3.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Matthew Sesterhenn | 4.50M | 3.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Squadron Capital Management LLC | 4.50M | 3.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Squadron Master Fund LP | 4.50M | 3.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | RA Capital Healthcare Fund, L.P. | 15.75M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Rajeev Shah | 15.75M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Peter Kolchinsky | 15.75M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | RA Capital Management, L.P. | 15.75M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Perceptive Life Sciences Master Fund, Ltd. | 15.20M | 10.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | PALI Palisade Bio, Inc. | Joseph Edelman | 15.20M | 10.0% | SCHEDULE 13G/A ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:46 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances